Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | S100B | P04271 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30690930 | 1.00 | HDAC6 (0.37) | HDAC6MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL21523292 | 0.81 | HDAC6 (0.39) | HDAC6MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29600727 | 0.80 | ALDH1A1 (0.40) | HDAC6MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL22401705 | 0.80 | ALDH1A1 (0.40) | HDAC6MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL571871 | 0.80 | ALDH1A1 (0.40) | HDAC6MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL29751992 | 0.76 | HDAC6 (0.44) | HDAC6MAPTALDH1A1KDM4ETSHR | |
| SCHEMBL10808616 | 0.70 | KDM4E (0.41) | HDAC6MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL10808625 | 0.70 | ALDH1A1 (0.41) | HDAC6MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL10479158 | 0.69 | MAPT (0.52) | HDAC6MAPTALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9570124 | 0.68 | RAB9A (0.40) | HDAC6MAPTSMN1; SMN2PGK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12607640-B2 | Mass spectrometry of steroidal compounds in multiplex samples | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2026-04-21 | — | — | US | claimed |
| US-20250216404-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVEST LLC (US) | 2025-07-03 | — | — | US | claimed |
| US-20230375575-A1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2023-11-23 | — | — | US | claimed |
| US-11808773-B2 | Mass spectrometry of steroidal compounds in multiplexed patient samples | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2023-11-07 | — | — | US | claimed |
| WO-2023155000-A1 | HIGH THROUGHPUT RAPID SCREENING OF VITAMIN D | MCMASTER UNIVERSITY (CA) | 2023-08-24 | — | — | WO | claimed |
| US-20210349109-A1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEXED PATIENT SAMPLES | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2021-11-11 | — | — | US | claimed |
| US-10955424-B2 | Mass spectrometry of steroidal compounds in multiplexed patient samples | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2021-03-23 | — | — | US | claimed |
| EP-3693734-A2 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | Quest Diagnostics Investments Incorporated (US) | 2020-08-12 | — | — | EP | claimed |
| EP-2510347-B1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEX SAMPLES | QUEST DIAGNOSTICS INVEST INC (US) | 2019-03-20 | — | — | EP | claimed |
| US-20170261523-A1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEXED PATIENT SAMPLES | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2017-09-14 | — | — | US | claimed |
| US-9506937-B2 | Mass spectrometry of steroidal compounds in multiplexed patient samples | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2016-11-29 | — | — | US | claimed |
| US-20160061848-A1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEXED PATIENT SAMPLES | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2016-03-03 | — | — | US | claimed |
| US-9034653-B2 | Mass spectrometry of steroidal compounds in multiplexed patient samples | QUEST DIAGNOSTICS INVESTMENTS INC. (US) | 2015-05-19 | — | — | US | claimed |
| US-20140051176-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2014-02-20 | — | — | US | claimed |
| US-20130137185-A1 | MASS SPECTROMETRY OF STEROIDAL COMPOUNDS IN MULTIPLEXED PATIENT SAMPLES | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2013-05-30 | — | — | US | claimed |
| US-20110240840-A1 | MASS SPECTROMETRIC DETERMINATION OF COOKSON-DERIVATIZED, NON-METABOLIZED VITAMIN D | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2011-10-06 | — | — | US | claimed |
| US-20110226944-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED | 2011-09-22 | — | — | US | claimed |
| US-7977117-B2 | Vitamin D metabolite determination utilizing mass spectrometry following derivatization | Quest Diagnostics Investments Incorprated (US) | 2011-07-12 | — | — | US | claimed |
| US-20110133068-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVESTMENTS LLC | 2011-06-09 | — | — | US | claimed |
| WO-2011068707-A1 | VITAMIN D METABOLITE DETERMINATION UTILIZING MASS SPECTROMETRY FOLLOWING DERIVATIZATION | QUEST DIAGNOSTICS INVESTMENTS INCORPORATED (US) | 2011-06-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12607640-B2 | Mass spectrometry of steroidal compounds in multiplex samples | CYP24A1, CYP2R1, SRD5A1 | HDAC6 2310/4885MAPT 2875/4885ALDH1A1 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.